Drug-induced cholestasis

Vinay Sundaram, Einar S. Björnsson

Rannsóknarafurð: Framlag til fræðitímaritsYfirlitsgreinritrýni

31 Tilvitnanir (Scopus)

Útdráttur

Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug-induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. (Hepatology Communications 2017;1:726–735).

Upprunalegt tungumálEnska
Síður (frá-til)726-735
Síðufjöldi10
FræðitímaritHepatology Communications
Bindi1
Númer tölublaðs8
DOI
ÚtgáfustaðaÚtgefið - okt. 2017

Athugasemd

Publisher Copyright:
© 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

Önnur efnisorð

  • Gallrás
  • Lifrarsjúkdómar
  • GAS12
  • Cholestasis
  • Chemical and Drug Induced Liver Injury

Fingerprint

Sökktu þér í rannsóknarefni „Drug-induced cholestasis“. Saman myndar þetta einstakt fingrafar.

Vitna í þetta